Surrey Heartlands

Joint Formulary & PAD

Cinacalcet hydrochloride - Secondary Hyperparathyroidism [in patients with end-stage renal disease on dialysis]

You are here : Home > Formulary Search > Cinacalcet hydrochloride - Secondary Hyperparathyroidism [in patients with end-stage renal disease on dialysis]

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NHSE
SPC
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Cinacalcet hydrochloride
Indication :
Secondary Hyperparathyroidism [in patients with end-stage renal disease on dialysis]
Group Name :
Keywords :
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Cinacalcet hydrochloride is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Secondary Hyperparathyroidism [in patients with end-stage renal disease on dialysis] .

  • No records returned.

Committee Recommendations (1)

06 Oct 21 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.

Treatment should remain with the specialist (RED) hospital only drug.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.